18 | | - | screen adults for HIV exposure and provide the results 5 |
---|
19 | | - | to such adults, with advice to consult with or seek 6 |
---|
20 | | - | treatment from a physician; authorizing pharmacists to 7 |
---|
21 | | - | dispense HIV preexposure prophylaxis drugs pursuant to 8 |
---|
22 | | - | a prescription; authorizing pharmacists to order and 9 |
---|
23 | | - | dispense HIV postexposure prophylaxis drugs pursuant 10 |
---|
24 | | - | to a written collaborative practice agreement with a 11 |
---|
25 | | - | physician; specifying requirements for the practice 12 |
---|
26 | | - | agreements; requiring the supervising physician to 13 |
---|
27 | | - | review the pharmacist's records a nd actions in 14 |
---|
28 | | - | accordance with the practice agreement; requiring 15 |
---|
29 | | - | pharmacists who enter into such practice agreements to 16 |
---|
30 | | - | submit the agreements to the Board of Pharmacy; 17 |
---|
31 | | - | requiring such pharmacists to provide certain written 18 |
---|
32 | | - | information when dispensing such dr ugs to patients; 19 |
---|
33 | | - | requiring pharmacists to comply with certain 20 |
---|
34 | | - | procedures under certain circumstances; requiring 21 |
---|
35 | | - | pharmacists, before ordering and dispensing HIV 22 |
---|
36 | | - | postexposure prophylaxis drugs, to be certified by the 23 |
---|
37 | | - | Board of Pharmacy; specifying minimum req uirements for 24 |
---|
38 | | - | the certification; requiring certain pharmacies to 25 |
---|
39 | | - | ENROLLED |
---|
40 | | - | CS/CS/HB 159, Engrossed 2 2024 Legislature |
---|
| 18 | + | screen for HIV exposure and order and dispense HIV 5 |
---|
| 19 | + | infection prevention drugs under a collaborative 6 |
---|
| 20 | + | practice agreement; requiring pharmacists to be 7 |
---|
| 21 | + | certified by the Board of Pharmacy before ordering and 8 |
---|
| 22 | + | dispensing HIV infection prevention drugs; requiring 9 |
---|
| 23 | + | the board, in consultation with the Board of Medicine 10 |
---|
| 24 | + | and the Board of Osteopathic Medicine, to adopt rules 11 |
---|
| 25 | + | for such certification; specifying minimum 12 |
---|
| 26 | + | requirements for the certification; requiring the 13 |
---|
| 27 | + | board to adopt rules; providing an effective date. 14 |
---|
| 28 | + | 15 |
---|
| 29 | + | Be It Enacted by the Legislature of the State of Florida: 16 |
---|
| 30 | + | 17 |
---|
| 31 | + | Section 1. This act may be cited as the "John W. Rheay 18 |
---|
| 32 | + | Act." 19 |
---|
| 33 | + | Section 2. Section 465.1861, Florida Statutes, is created 20 |
---|
| 34 | + | to read: 21 |
---|
| 35 | + | 465.1861 Ordering and dispensing HIV infection prevention 22 |
---|
| 36 | + | drugs.— 23 |
---|
| 37 | + | (1) As used in this section, the term: 24 |
---|
| 38 | + | (a) "HIV" means the human immunodeficiency virus. 25 |
---|
| 39 | + | |
---|
| 40 | + | CS/CS/HB 159, Engrossed 1 2024 |
---|
51 | | - | submit an access-to-care plan to the Board of Pharmacy 26 |
---|
52 | | - | and the Department of Health annually; authorizing the 27 |
---|
53 | | - | board to fine or place certain prohibitions on a 28 |
---|
54 | | - | pharmacy that does not comply wi th the requirements 29 |
---|
55 | | - | for access-to-care plans; specifying requirements for 30 |
---|
56 | | - | the plans; requiring the board to adopt rules; 31 |
---|
57 | | - | providing an effective date. 32 |
---|
58 | | - | 33 |
---|
59 | | - | Be It Enacted by the Legislature of the State of Florida: 34 |
---|
60 | | - | 35 |
---|
61 | | - | Section 1. This act may be cited as th e "John W. Rheay 36 |
---|
62 | | - | Act." 37 |
---|
63 | | - | Section 2. Section 465.1861, Florida Statutes, is created 38 |
---|
64 | | - | to read: 39 |
---|
65 | | - | 465.1861 Ordering and dispensing HIV infection prevention 40 |
---|
66 | | - | drugs.— 41 |
---|
67 | | - | (1) As used in this section, the term: 42 |
---|
68 | | - | (a) "HIV" means the human immunodeficiency virus. 43 |
---|
69 | | - | (b) "HIV infection prevention drug" means preexposure 44 |
---|
70 | | - | prophylaxis, postexposure prophylaxis, and any other drug 45 |
---|
71 | | - | approved by the United States Food and Drug Administration for 46 |
---|
72 | | - | the prevention of HIV infection. 47 |
---|
73 | | - | (c) "Postexposure prophylaxis" means a drug o r drug 48 |
---|
74 | | - | combination that meets the clinical eligibility recommendations 49 |
---|
75 | | - | of the United States Centers for Disease Control and Prevention 50 |
---|
76 | | - | ENROLLED |
---|
77 | | - | CS/CS/HB 159, Engrossed 2 2024 Legislature |
---|
| 51 | + | (b) "HIV infection prevention drug" means preexposure 26 |
---|
| 52 | + | prophylaxis, postexposure prophylaxis, and any other drug 27 |
---|
| 53 | + | approved by the United States Food and Drug Administration for 28 |
---|
| 54 | + | the prevention of HIV infection. 29 |
---|
| 55 | + | (c) "Postexposure prophylaxis" means a drug or drug 30 |
---|
| 56 | + | combination that meets the clinical eligibility recommendations 31 |
---|
| 57 | + | of the United States Centers for Disease Contro l and Prevention 32 |
---|
| 58 | + | guidelines for antiretroviral treatment following potential 33 |
---|
| 59 | + | exposure to HIV. 34 |
---|
| 60 | + | (d) "Preexposure prophylaxis" means a drug or drug 35 |
---|
| 61 | + | combination that meets the clinical eligibility recommendations 36 |
---|
| 62 | + | of the United States Centers for Disease Cont rol and Prevention 37 |
---|
| 63 | + | guidelines for antiretroviral treatment for the prevention of 38 |
---|
| 64 | + | HIV transmission. 39 |
---|
| 65 | + | (2) A pharmacist may screen an adult for HIV exposure and 40 |
---|
| 66 | + | provide the results to the adult, with the advice that the 41 |
---|
| 67 | + | patient should seek further medical co nsultation or treatment 42 |
---|
| 68 | + | from a physician. 43 |
---|
| 69 | + | (3) A pharmacist may dispense HIV preexposure prophylaxis 44 |
---|
| 70 | + | drugs pursuant to a valid prescription issued by a licensed 45 |
---|
| 71 | + | health care practitioner authorized by law to prescribe such 46 |
---|
| 72 | + | drugs. 47 |
---|
| 73 | + | (4) A pharmacist who is certified under subsection (6) may 48 |
---|
| 74 | + | order and dispense HIV postexposure prophylaxis drugs pursuant 49 |
---|
| 75 | + | to a written collaborative practice agreement between the 50 |
---|
| 76 | + | |
---|
| 77 | + | CS/CS/HB 159, Engrossed 1 2024 |
---|
88 | | - | guidelines for antiretroviral treatment following potential 51 |
---|
89 | | - | exposure to HIV. 52 |
---|
90 | | - | (d) "Preexposure prophylaxis" means a drug or drug 53 |
---|
91 | | - | combination that meets the clinical eligibility recommendations 54 |
---|
92 | | - | of the United States Centers for Disease Control and Prevention 55 |
---|
93 | | - | guidelines for antiretroviral treatment for the prevention of 56 |
---|
94 | | - | HIV transmission. 57 |
---|
95 | | - | (2) A pharmacist may screen an adult for HIV exposure and 58 |
---|
96 | | - | provide the results to the adult, with the advice that the 59 |
---|
97 | | - | patient should seek further medical consultation or treatment 60 |
---|
98 | | - | from a physician. 61 |
---|
99 | | - | (3) A pharmacist may dispense HIV preexposure prophylaxis 62 |
---|
100 | | - | drugs pursuant to a valid prescripti on issued by a licensed 63 |
---|
101 | | - | health care practitioner authorized by law to prescribe such 64 |
---|
102 | | - | drugs. 65 |
---|
103 | | - | (4) A pharmacist who is certified under subsection (6) may 66 |
---|
104 | | - | order and dispense HIV postexposure prophylaxis drugs pursuant 67 |
---|
105 | | - | to a written collaborative practice agre ement between the 68 |
---|
106 | | - | pharmacist and a physician licensed under chapter 458 or chapter 69 |
---|
107 | | - | 459. 70 |
---|
108 | | - | (a) A written collaborative practice agreement between a 71 |
---|
109 | | - | pharmacist and a physician under this section must include, at a 72 |
---|
110 | | - | minimum, all of the following: 73 |
---|
111 | | - | 1. Terms and conditions relating to the screening for HIV 74 |
---|
112 | | - | and the ordering and dispensing of HIV postexposure prophylaxis 75 |
---|
113 | | - | ENROLLED |
---|
114 | | - | CS/CS/HB 159, Engrossed 2 2024 Legislature |
---|
| 88 | + | pharmacist and a physician licensed under chapter 458 or chapter 51 |
---|
| 89 | + | 459. 52 |
---|
| 90 | + | (a) A written collaborative practice agreement between a 53 |
---|
| 91 | + | pharmacist and a physician under this section must include, at a 54 |
---|
| 92 | + | minimum, all of the following: 55 |
---|
| 93 | + | 1. Terms and conditions relating to the screening for HIV 56 |
---|
| 94 | + | and the ordering and dispensing of HIV postexposure prophylaxis 57 |
---|
| 95 | + | drugs by the pharmacist. Such terms and conditions must be 58 |
---|
| 96 | + | appropriate for the pharmacist's training. 59 |
---|
| 97 | + | 2. Specific categories of patients the pharmacist is 60 |
---|
| 98 | + | authorized to screen for HIV and for whom the pharmacist may 61 |
---|
| 99 | + | order and dispense HIV postexposure pr ophylaxis drugs. 62 |
---|
| 100 | + | 3. The physician's instructions for obtaining relevant 63 |
---|
| 101 | + | patient medical history for the purpose of identifying 64 |
---|
| 102 | + | disqualifying health conditions, adverse reactions, and 65 |
---|
| 103 | + | contraindications to the use of HIV postexposure prophylaxis 66 |
---|
| 104 | + | drugs. 67 |
---|
| 105 | + | 4. A process and schedule for the physician to review the 68 |
---|
| 106 | + | pharmacist's actions under the practice agreement. 69 |
---|
| 107 | + | 5. Evidence of the pharmacist's current certification by 70 |
---|
| 108 | + | the board as provided in subsection (6). 71 |
---|
| 109 | + | 6. Any other requirements as established by th e board in 72 |
---|
| 110 | + | consultation with the Board of Medicine and the Board of 73 |
---|
| 111 | + | Osteopathic Medicine. 74 |
---|
| 112 | + | (b) A physician who has entered into a written 75 |
---|
| 113 | + | |
---|
| 114 | + | CS/CS/HB 159, Engrossed 1 2024 |
---|
125 | | - | drugs by the pharmacist. Such terms and conditions must be 76 |
---|
126 | | - | appropriate for the pharmacist's training. 77 |
---|
127 | | - | 2. Specific categories of pat ients the pharmacist is 78 |
---|
128 | | - | authorized to screen for HIV and for whom the pharmacist may 79 |
---|
129 | | - | order and dispense HIV postexposure prophylaxis drugs. 80 |
---|
130 | | - | 3. A requirement that the pharmacist maintain records for 81 |
---|
131 | | - | any HIV postexposure prophylaxis drugs ordered and dispe nsed 82 |
---|
132 | | - | under the collaborative practice agreement. 83 |
---|
133 | | - | 4. The physician's instructions for obtaining relevant 84 |
---|
134 | | - | patient medical history for the purpose of identifying 85 |
---|
135 | | - | disqualifying health conditions, adverse reactions, and 86 |
---|
136 | | - | contraindications to the use of HIV pos texposure prophylaxis 87 |
---|
137 | | - | drugs. 88 |
---|
138 | | - | 5. A process and schedule for the physician to review the 89 |
---|
139 | | - | pharmacist's records and actions under the practice agreement. 90 |
---|
140 | | - | 6. Evidence of the pharmacist's current certification by 91 |
---|
141 | | - | the board as provided in subsection (6). 92 |
---|
142 | | - | 7. Any other requirements as established by the board with 93 |
---|
143 | | - | the approval of the Board of Medicine and the Board of 94 |
---|
144 | | - | Osteopathic Medicine. 95 |
---|
145 | | - | (b) A physician who has entered into a written 96 |
---|
146 | | - | collaborative practice agreement pursuant to this section is 97 |
---|
147 | | - | responsible for reviewing the pharmacist's records and actions 98 |
---|
148 | | - | to ensure compliance with the agreement. 99 |
---|
149 | | - | (c) The pharmacist shall submit a copy of the written 100 |
---|
150 | | - | ENROLLED |
---|
151 | | - | CS/CS/HB 159, Engrossed 2 2024 Legislature |
---|
| 125 | + | collaborative practice agreement pursuant to this section is 76 |
---|
| 126 | + | responsible for reviewing the pharmacist's actions to en sure 77 |
---|
| 127 | + | compliance with the agreement. 78 |
---|
| 128 | + | (c) The pharmacist shall submit a copy of the written 79 |
---|
| 129 | + | collaborative practice agreement to the board. 80 |
---|
| 130 | + | (5) A pharmacist who orders and dispenses HIV postexposure 81 |
---|
| 131 | + | prophylaxis drugs pursuant to subsection (4) must provid e the 82 |
---|
| 132 | + | patient with written information advising the patient to seek 83 |
---|
| 133 | + | follow-up care from his or her primary care physician. If the 84 |
---|
| 134 | + | patient indicates that he or she lacks regular access to primary 85 |
---|
| 135 | + | care, the pharmacist must comply with the procedures of the 86 |
---|
| 136 | + | pharmacy's approved access -to-care plan as provided in 87 |
---|
| 137 | + | subsection (7). 88 |
---|
| 138 | + | (6) To provide services under a collaborative practice 89 |
---|
| 139 | + | agreement pursuant to this section, a pharmacist must be 90 |
---|
| 140 | + | certified by the board, according to rules adopted by the board 91 |
---|
| 141 | + | in consultation with the Board of Medicine and the Board of 92 |
---|
| 142 | + | Osteopathic Medicine. To be certified, a pharmacist must, at a 93 |
---|
| 143 | + | minimum, meet all of the following criteria: 94 |
---|
| 144 | + | (a) Hold an active and unencumbered license to practice 95 |
---|
| 145 | + | pharmacy under this chapter. 96 |
---|
| 146 | + | (b) Be engaged in the active practice of pharmacy. 97 |
---|
| 147 | + | (c) Have earned a degree of doctor of pharmacy or have 98 |
---|
| 148 | + | completed at least 3 years of experience as a licensed 99 |
---|
| 149 | + | pharmacist. 100 |
---|
| 150 | + | |
---|
| 151 | + | CS/CS/HB 159, Engrossed 1 2024 |
---|
162 | | - | collaborative practice agreement to the board. 101 |
---|
163 | | - | (5) A pharmacist who orders and dispenses HIV postexposure 102 |
---|
164 | | - | prophylaxis drugs pursuant to subsection (4) must provide the 103 |
---|
165 | | - | patient with written information advising the patient to seek 104 |
---|
166 | | - | follow-up care from his or her primary care physician. If the 105 |
---|
167 | | - | patient indicates that he or she lacks regular access to primary 106 |
---|
168 | | - | care, the pharmacist must comply with the procedures of the 107 |
---|
169 | | - | pharmacy's approved access -to-care plan as provided in 108 |
---|
170 | | - | subsection (7). 109 |
---|
171 | | - | (6) To provide services under a collaborative practice 110 |
---|
172 | | - | agreement pursuant to this section, a pharmacist must be 111 |
---|
173 | | - | certified by the board, according to rules adopted by the board. 112 |
---|
174 | | - | To be certified, a pharmacist must, at a minimum, meet all of 113 |
---|
175 | | - | the following criteria: 114 |
---|
176 | | - | (a) Hold an active and unencumbered license to practice 115 |
---|
177 | | - | pharmacy under this chapter. 116 |
---|
178 | | - | (b) Be engaged in the active pra ctice of pharmacy. 117 |
---|
179 | | - | (c) Have earned a degree of doctor of pharmacy or have 118 |
---|
180 | | - | completed at least 3 years of experience as a licensed 119 |
---|
181 | | - | pharmacist. 120 |
---|
182 | | - | (d) Maintain at least $250,000 of liability coverage. A 121 |
---|
183 | | - | pharmacist who maintains liability coverage pursuant to s. 122 |
---|
184 | | - | 465.1865 or s. 465.1895 satisfies this requirement. 123 |
---|
185 | | - | (e) Have completed a course approved by the board, in 124 |
---|
186 | | - | consultation with the Board of Medicine and the Board of 125 |
---|
187 | | - | ENROLLED |
---|
188 | | - | CS/CS/HB 159, Engrossed 2 2024 Legislature |
---|
| 162 | + | (d) Maintain at least $250,000 of liability coverage. A 101 |
---|
| 163 | + | pharmacist who maintains liabi lity coverage pursuant to s. 102 |
---|
| 164 | + | 465.1865 or s. 465.1895 satisfies this requirement. 103 |
---|
| 165 | + | (e) Have completed a course approved by the board, in 104 |
---|
| 166 | + | consultation with the Board of Medicine and the Board of 105 |
---|
| 167 | + | Osteopathic Medicine, which includes, at a minimum, instructio n 106 |
---|
| 168 | + | on all of the following: 107 |
---|
| 169 | + | 1. Performance of patient assessments. 108 |
---|
| 170 | + | 2. Point-of-care testing procedures. 109 |
---|
| 171 | + | 3. Safe and effective treatment of HIV exposure with HIV 110 |
---|
| 172 | + | infection prevention drugs, including, but not limited to, 111 |
---|
| 173 | + | consideration of the side effec ts of the drug dispensed and the 112 |
---|
| 174 | + | patient's diet and activity levels. 113 |
---|
| 175 | + | 4. Identification of contraindications. 114 |
---|
| 176 | + | 5. Identification of patient comorbidities in individuals 115 |
---|
| 177 | + | with HIV requiring further medical evaluation and treatment, 116 |
---|
| 178 | + | including, but not limit ed to, cardiovascular disease, lung and 117 |
---|
| 179 | + | liver cancer, chronic obstructive lung disease, and diabetes 118 |
---|
| 180 | + | mellitus. 119 |
---|
| 181 | + | (7)(a) A pharmacy in which a pharmacist is providing 120 |
---|
| 182 | + | services under a written collaborative practice agreement 121 |
---|
| 183 | + | pursuant to subsection (4) must submit an access-to-care plan to 122 |
---|
| 184 | + | the board and department annually. 123 |
---|
| 185 | + | (b) An access-to-care plan shall assist patients in 124 |
---|
| 186 | + | gaining access to appropriate care settings when they present to 125 |
---|
| 187 | + | |
---|
| 188 | + | CS/CS/HB 159, Engrossed 1 2024 |
---|
199 | | - | Osteopathic Medicine, which includes, at a minimum, instruction 126 |
---|
200 | | - | on all of the following : 127 |
---|
201 | | - | 1. Performance of patient assessments. 128 |
---|
202 | | - | 2. Point-of-care testing procedures. 129 |
---|
203 | | - | 3. Safe and effective treatment of HIV exposure with HIV 130 |
---|
204 | | - | infection prevention drugs, including, but not limited to, 131 |
---|
205 | | - | consideration of the side effects of the drug dispensed and the 132 |
---|
206 | | - | patient's diet and activity levels. 133 |
---|
207 | | - | 4. Identification of contraindications. 134 |
---|
208 | | - | 5. Identification of patient comorbidities in individuals 135 |
---|
209 | | - | with HIV requiring further medical evaluation and treatment, 136 |
---|
210 | | - | including, but not limited to, cardiovascular dis ease, lung and 137 |
---|
211 | | - | liver cancer, chronic obstructive lung disease, and diabetes 138 |
---|
212 | | - | mellitus. 139 |
---|
213 | | - | (f) Any other criteria as established by the board with 140 |
---|
214 | | - | the approval of the Board of Medicine and the Board of 141 |
---|
215 | | - | Osteopathic Medicine. 142 |
---|
216 | | - | (7)(a) A pharmacy in which a phar macist is providing 143 |
---|
217 | | - | services under a written collaborative practice agreement 144 |
---|
218 | | - | pursuant to subsection (4) must submit an access -to-care plan to 145 |
---|
219 | | - | the board and department annually. If the board or the 146 |
---|
220 | | - | department determines that a pharmacy has failed to submit an 147 |
---|
221 | | - | access-to-care plan required under this section or if a 148 |
---|
222 | | - | pharmacy's access-to-care plan does not comply with this section 149 |
---|
223 | | - | or applicable rules of the board, the board must notify the 150 |
---|
224 | | - | ENROLLED |
---|
225 | | - | CS/CS/HB 159, Engrossed 2 2024 Legislature |
---|
226 | | - | |
---|
227 | | - | |
---|
228 | | - | |
---|
229 | | - | CODING: Words stricken are deletions; words underlined are additions. |
---|
230 | | - | hb0159-05-er |
---|
231 | | - | Page 7 of 8 |
---|
232 | | - | F L O R I D A H O U S E O F R E P R E S E N T A T I V E S |
---|
233 | | - | |
---|
234 | | - | |
---|
235 | | - | |
---|
236 | | - | pharmacy of its noncompliance and the pharmacy must submit an 151 |
---|
237 | | - | access-to-care plan that brings the pharmacy into compliance 152 |
---|
238 | | - | according to parameters provided in board rule. The board may 153 |
---|
239 | | - | fine a pharmacy that fails to comply with this paragraph or may 154 |
---|
240 | | - | prohibit such pharmacy from allowing its pharmacists to screen 155 |
---|
241 | | - | adults for HIV exposure or order and dispense HIV postexposure 156 |
---|
242 | | - | prophylaxis drugs under a collaborative practice agreement until 157 |
---|
243 | | - | the pharmacy complies with this paragraph. 158 |
---|
244 | | - | (b) An access-to-care plan shall assist patients in 159 |
---|
245 | | - | gaining access to appropriate care settings wh en they present to 160 |
---|
246 | | - | a pharmacist for HIV screening and indicate that they lack 161 |
---|
247 | | - | regular access to primary care. An access -to-care plan must 162 |
---|
248 | | - | include, but need not be limited to: 163 |
---|
249 | | - | 1. Procedures to educate such patients about care that 164 |
---|
250 | | - | would be best provided i n a primary care setting and the 165 |
---|
251 | | - | importance of receiving regular primary care. 166 |
---|
252 | | - | 2. The pharmacy's plan for collaborative partnership with 167 |
---|
253 | | - | one or more nearby federally qualified health centers, county 168 |
---|
254 | | - | health departments, or other primary care settings. The goals of 169 |
---|
255 | | - | such partnership must include, but need not be limited to, 170 |
---|
256 | | - | protocols for identifying and appropriately referring a patient 171 |
---|
257 | | - | who has presented to the pharmacist for HIV screening or access 172 |
---|
258 | | - | to HIV infection prevention drugs and indicates that he or she 173 |
---|
259 | | - | lacks regular access to primary care. 174 |
---|
260 | | - | (8) The board shall adopt rules to implement this section. 175 |
---|
261 | | - | ENROLLED |
---|
262 | | - | CS/CS/HB 159, Engrossed 2 2024 Legislature |
---|
263 | | - | |
---|
264 | | - | |
---|
265 | | - | |
---|
266 | | - | CODING: Words stricken are deletions; words underlined are additions. |
---|
267 | | - | hb0159-05-er |
---|
268 | | - | Page 8 of 8 |
---|
269 | | - | F L O R I D A H O U S E O F R E P R E S E N T A T I V E S |
---|
270 | | - | |
---|
271 | | - | |
---|
272 | | - | |
---|
273 | | - | Section 3. This act shall take effect July 1, 2024. 176 |
---|
| 199 | + | a pharmacist for HIV screening and indicate that they lack 126 |
---|
| 200 | + | regular access to primary care. An access -to-care plan must 127 |
---|
| 201 | + | include: 128 |
---|
| 202 | + | 1. Procedures to educate such patients about care that 129 |
---|
| 203 | + | would be best provided in a primary care setting and the 130 |
---|
| 204 | + | importance of receiving regular primary care. 131 |
---|
| 205 | + | 2. The pharmacy's plan for collabor ative partnership with 132 |
---|
| 206 | + | one or more nearby federally qualified health centers, county 133 |
---|
| 207 | + | health departments, or other primary care settings. The goals of 134 |
---|
| 208 | + | such partnership must include, but need not be limited to, 135 |
---|
| 209 | + | protocols for identifying and appropriately ref erring a patient 136 |
---|
| 210 | + | who has presented to the pharmacist for HIV screening or access 137 |
---|
| 211 | + | to HIV infection prevention drugs and indicates that he or she 138 |
---|
| 212 | + | lacks regular access to primary care. 139 |
---|
| 213 | + | (8) The board shall adopt rules to implement this section. 140 |
---|
| 214 | + | Section 3. This act shall take effect July 1, 2024. 141 |
---|